





### Xyrem Prior Authorization

Initial Therapy		
You must answer ALL of the following questions		
1. Is this a first time request for this medication under the patient's pharmacy benefit? <b>(Please Circle)</b>  <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown  <i>This will be verified in the patient's claims history. If not found, patient will be subject to initial criteria. *To avoid delay in coverage determination, please fill out the initial section of the form if this is unknown.*</i>  <i>If No, please complete Repeat Therapy section below</i>		
2. Are the patient and physician enrolled in the Xyrem Success Program?	Y	N
3. Will the patient use the prescribed medication in combination with a sedative hypnotic agent or alcohol?	Y	N
4. Does the patient have a succinic semialdehyde dehydrogenase deficiency?	Y	N
5. What is the patient's diagnosis? <b>(Please Circle)</b> <input type="checkbox"/> Narcolepsy with excessive daytime sleepiness <input type="checkbox"/> Cataplexy in narcolepsy <input type="checkbox"/> Other: _____		
6. Has the patient had a trial and inadequate response, contraindication, or intolerance to an amphetamine or methylphenidate product (e.g., methylphenidate, dextroamphetamine, or mixed amphetamine salt)?	Y	N
7. Has the patient had a trial and inadequate response, contraindication or intolerance to a CNS stimulant (e.g., modafinil (Provigil), armodafinil (Nuvigil))?	Y	N

Repeat Therapy		
You must answer ALL of the following questions		
1. Is this a first time request for this medication under the patient's pharmacy benefit? <b>(Please Circle)</b>  <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown  <i>This will be verified in the patient's claims history. If not found, patient will be subject to initial criteria. *To avoid delay in coverage determination, please fill out the initial section of the form if this is unknown.*</i>  <i>If Yes, please complete Initial Therapy section above</i>		
2. Is the patient benefiting from therapy as evidenced by improved wakefulness or reduced fatigue?	Y	N
3. Is the patient concomitantly receiving a sedative hypnotic agent or alcohol?	Y	N



**Catamaran Prior Authorization Department**

**Phone: 800-626-0072**

**Fax: 866-511-2202**

**Catamaran (UHA's Pharmacy Benefits Manager)**

Comments: \_\_\_\_\_  
*Information given on this form is accurate as of this date.*

\_\_\_\_\_  
**Prescriber or Authorized Signature**

\_\_\_\_\_  
**Date**

\_\_\_\_\_  
**Authorized Medical Staff – Name/Title**

**Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department at 800-626-0072.**

**I understand that Catamaran's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).**